Polydex Pharmaceuticals Limited
POLXF · OTC
1/31/2010 | 10/31/2009 | 7/31/2009 | 4/30/2009 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.02 | -0.00 | 0.02 |
| FCF Yield | -19.63% | -9.38% | -13.62% | -47.23% |
| EV / EBITDA | -1.54 | -22.27 | -5.24 | -24.86 |
| Quality | ||||
| ROIC | -29.73% | -3.65% | -8.13% | -3.95% |
| Gross Margin | -16.66% | 6.72% | -16.19% | 20.16% |
| Cash Conversion Ratio | 0.10 | 0.44 | 0.25 | 4.20 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.89% | -10.41% | -8.97% | -10.25% |
| Free Cash Flow Growth | -51.15% | 31.14% | 38.92% | -142.93% |
| Safety | ||||
| Net Debt / EBITDA | -0.90 | -11.03 | -2.46 | -15.74 |
| Interest Coverage | -99.63 | -14.68 | -34.86 | -14.12 |
| Efficiency | ||||
| Inventory Turnover | 1.05 | 0.82 | 1.34 | 0.70 |
| Cash Conversion Cycle | 92.01 | 102.33 | 85.58 | 145.96 |